| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 09/27/2001 | WO2001070209A2 Mono- and disaccharides for the treatment of nitric oxide related disorders |
| 09/27/2001 | WO2001070199A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 09/27/2001 | WO2001060822A8 Amino acid derivatives and use thereof as nep, ace and ece inhibitors |
| 09/27/2001 | WO2001032662A3 Oxygen containing spirocondensed heterocyclic compounds and pharmaceutical compositions comprising same for partial coordination of calcium |
| 09/27/2001 | WO2001019992A3 FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES |
| 09/27/2001 | WO2001019829A3 Pyrazolopyrimidines as therapeutic agents |
| 09/27/2001 | WO2001016296A3 Use of cytokines, cells, and mitogens to inhibit graft versus host disease |
| 09/27/2001 | US20010025108 Thrombosis diseases |
| 09/27/2001 | US20010025044 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli |
| 09/27/2001 | US20010025041 Amidino protease inhibitors |
| 09/27/2001 | US20010025039 Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity |
| 09/27/2001 | US20010025036 Modifying the structure of a 1alpha-hydroxylated vitamin D compound to increase its in vivo activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents 1alphahydroxy in axial orientation |
| 09/27/2001 | US20010024813 Human dendriac and brainiac-3 |
| 09/27/2001 | US20010024664 Alzheimer's diseases; central nervous system disorders; antiinflammatory agent; solvent extraction from plants |
| 09/27/2001 | US20010024658 A delayed release pharmaceutical dosage form for oral administration of heparin comprising a low molecular weight heparin, a bile salt or acid, and a surfactant selected from hydrophilc and lipophilic, and a means for sustained release |
| 09/27/2001 | US20010024647 Single chain variable region immunoglobulin (ScFv) fragment antibody that binds selectively to the active conformation of human von Willebrand Factor (vWF) and the antibody inhibits the binding of vWF to platelets |
| 09/27/2001 | US20010024637 Novel compositions for use in embolizing blood vessels |
| 09/27/2001 | DE10014645A1 New amidino-aryl substituted biphenyl derivatives and analogs as Factor Xa inhibitors, are useful for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy or angina pectoris |
| 09/27/2001 | CA2404115A1 The use of peg-hirudin as an anticoagulant agent in the extracorporeal treatment of blood |
| 09/27/2001 | CA2404112A1 Sustained release delivery systems for solutes |
| 09/27/2001 | CA2403828A1 Inhibitors of p38 |
| 09/27/2001 | CA2403818A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 09/27/2001 | CA2403572A1 Fibroblast growth factor receptor-like molecules and uses thereof |
| 09/27/2001 | CA2403558A1 Thrombin inhibitors |
| 09/27/2001 | CA2403553A1 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 09/27/2001 | CA2403075A1 Mono- and disaccharides for the treatment of nitric oxide related disorders |
| 09/27/2001 | CA2402836A1 Process for preparing crystalline form i of cabergoline |
| 09/27/2001 | CA2402763A1 Proteases |
| 09/27/2001 | CA2402747A1 G-protein associated molecules |
| 09/27/2001 | CA2402596A1 Anti-tissue factor antibodies with enhanced anticoagulant potency |
| 09/27/2001 | CA2402572A1 3-oxy-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadazine-1,1-dioxide derivatives having diuretic and/or natriuretic activity |
| 09/27/2001 | CA2401908A1 Amorphous torasemide modification |
| 09/27/2001 | CA2401870A1 Cyclic .beta.-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-.alpha. |
| 09/27/2001 | CA2400168A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/26/2001 | EP1136084A1 Compositions containing thrombin and process for their manufacture |
| 09/26/2001 | EP1135534A1 Use of factor x polymorphism in the diagnosis and treatment of factor x and/or factor xa mediated diseases |
| 09/26/2001 | EP1135485A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 09/26/2001 | EP1135484A2 Gtpase associated proteins |
| 09/26/2001 | EP1135468A1 Virus vectors and methods of making and administering the same |
| 09/26/2001 | EP1135465A2 Human brain endothelial cells and growth medium and method for expansion of primitive cd34+cd38- bone marrow stem cells |
| 09/26/2001 | EP1135414A2 Allo and auto-reactive t-cell epitopes |
| 09/26/2001 | EP1135391A1 Novel triazolo(4,5-d)pyrimidine compounds |
| 09/26/2001 | EP1135371A1 Beta-alanine derivatives as alpha 4 integrin inhibitors |
| 09/26/2001 | EP1135167A2 Methods and formulations for reducing circulating antibodies |
| 09/26/2001 | EP1135149A1 Pgc-1, a novel brown fat ppar gamma coactivator |
| 09/26/2001 | EP1135139A1 Micronized eplerenone compositions |
| 09/26/2001 | EP1135131A1 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
| 09/26/2001 | EP1135122A2 Use of amtolmetin guacyl as an antiinflammatory drug |
| 09/26/2001 | EP1135023A1 Aminobenzisoxazole compounds and libraries thereof |
| 09/26/2001 | EP0775141B1 Phenyl xanthine derivatives |
| 09/26/2001 | EP0767796B1 Chemotactic protein |
| 09/26/2001 | CN1314895A Substituted piperazones and their therapeutic use |
| 09/26/2001 | CN1314893A IL-8 receptor antanonists |
| 09/26/2001 | CN1314887A Ester of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5HT2A receptor antagonist MDL 110,907 |
| 09/26/2001 | CN1314347A Six kinds of isoquinoline alkaloid |
| 09/26/2001 | CN1071760C N-terminally chemically modified protein composition and methods |
| 09/26/2001 | CN1071759C Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and use thereof |
| 09/25/2001 | US6294562 Salts of ethyl 3-(2-(4-(4-amino-imino-methyl)phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl)acetylamino)-3-phenylpropionate |
| 09/25/2001 | US6294561 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/25/2001 | US6294377 Adenoviral vectors of canine origin |
| 09/25/2001 | US6294353 Targeted hetero-association of recombinant proteins to multi-functional complexes |
| 09/25/2001 | US6294347 Human FCγ receptor III |
| 09/25/2001 | CA1341298C Human serum albumin fragment |
| 09/25/2001 | CA1341296C 2-azabicycloalkane-3-carboxylic acid derivatives, processes for their preparation, agents containing these compounds and their use |
| 09/20/2001 | WO2001068888A2 Production of chimeric capsid vectors |
| 09/20/2001 | WO2001068860A1 Antibodies to human cd154 |
| 09/20/2001 | WO2001068720A1 Embolic compositions |
| 09/20/2001 | WO2001068697A2 Methods and compositions for immunoregulation |
| 09/20/2001 | WO2001068653A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | WO2001068643A2 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | WO2001068591A1 Carboxylic acid derivatives as ip antagonists |
| 09/20/2001 | WO2001068570A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068569A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068568A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068147A2 Synthetic oligonucleotides as inducers of erythroid differentiation |
| 09/20/2001 | WO2001068109A1 Modified factor viii |
| 09/20/2001 | WO2001068099A1 Modulation of cardiovascular injury |
| 09/20/2001 | WO2001068084A1 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068033A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001019819A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 09/20/2001 | WO2001016603A3 Analysis and treatment of body weight and eating disorders |
| 09/20/2001 | WO2001014593A3 A method for producing quality assured biological sample and composition containing the same |
| 09/20/2001 | WO2001007065B1 PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES |
| 09/20/2001 | WO2000059903A3 Universal die holder assembly for press brakes |
| 09/20/2001 | WO2000047553A8 ALKENYL AND ALKYNYL COMPOUNDS AS INHIBITORS OF FACTOR Xa |
| 09/20/2001 | WO2000027378A3 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 09/20/2001 | WO2000009537A3 Compounds having growth hormone releasing activity |
| 09/20/2001 | US20010023292 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4 -(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine, for example |
| 09/20/2001 | US20010023291 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| 09/20/2001 | US20010023244 Thrombin inhibitors |
| 09/20/2001 | US20010022969 Sepsis therapy |
| 09/20/2001 | EP1143960A3 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 09/20/2001 | DE10012732A1 Thrombin composition, for use as hemostatic or as a component of fibrin glues, comprises non-covalently bonded inhibitor for stabilization |
| 09/20/2001 | CA2403679A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403062A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2402898A1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | CA2402891A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2402645A1 Modulation of cardiovascular injury |
| 09/20/2001 | CA2402427A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |